Guggenheim Capital LLC Clovis Oncology, Inc. Transaction History

Guggenheim Capital LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2019 Feb 14, 2020	SELL	$3.0 - $16.43 $435,324 - $2.38 Million	-145,108 Closed	0 $0
Q3 2019 Nov 14, 2019	BUY	$3.93 - $15.35 $236,892 - $925,267	60,278 Added 71.06%	145,108 $570,000
Q2 2019 Aug 14, 2019	BUY	$12.81 - $25.67 $186,167 - $373,062	14,533 Added 20.67%	84,830 $1.26 Million
Q1 2019 May 15, 2019	SELL	$17.66 - $30.28 $164,644 - $282,300	-9,323 Reduced 11.71%	70,297 $1.75 Million
Q4 2018 Feb 14, 2019	BUY	$11.63 - $32.67 $39,414 - $110,718	3,389 Added 4.45%	79,620 $1.43 Million

Q3 2018 Nov 14, 2018	BUY	$29.37 - $49.48 $340,574 - $573,770	11,596 Added 17.94%	76,231 $2.24 Million
Q2 2018 Aug 14, 2018	BUY	$42.06 - $62.4 $411,346 - $610,272	9,780 Added 17.83%	64,635 $2.94 Million
Q1 2018 May 15, 2018	BUY	$50.12 - $67.72 $113,371 - $153,182	2,262 Added 4.3%	54,855 $2.9 Million
Q4 2017 Feb 14, 2018	SELL	$57.69 - $84.58 $879,714 - $1.29 Million	-15,249 Reduced 22.48%	52,593 $3.58 Million
Q3 2017 Nov 14, 2017	BUY	$67.17 - $84.81 $4.56 Million - $5.75 Million	67,842	67,842 $5.59 Million

166

Ticker CLVS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 144,480,000
Market Cap $13M
Description
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. In the U.S., the company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or pr...

Get notified when there are updates to the investment portfolio of Guggenheim Capital LLC, based on Form 13F filings with the SEC.

Stay updated on Guggenheim Capital LLC with notifications on news.